Cyient DLM Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/grnl44j0i6sfisc9dkewwnmh.pdf

Key Takeaways


Revenue & Profitability

Shrinivas Kulkarni: "The 50% growth in the revenue is translating to a 30% growth in the EBITDA. That's largely because of investing in SG&A. I think that is where the bulk of the investments have been made. And this is a very conscious call to build an organization which will cater to 30 crore to, in the short term to about 50 crore in the long term."

Order Book & Pipeline

Anthony Montalbano: "A lot of our programs are with larger clients on these bigger, more strategic programs. And the award of those is not a continual monthly or even quarterly type of business award."

Margins & Cost Structure

Shrinivas Kulkarni: "I think we will get to 11%-12% very quickly. It will probably stay around the 10% for some time. As we find other opportunities where the mix of the business changes and then we get the benefits of the scale, we will start inching towards 11%-12%."

Working Capital & Cash Flow

Shrinivas Kulkarni: "No, on a full-year basis, we aspire to break-even, but we might be a little bit shy of that because we have consumed almost INR230 crores in the first nine months. So, to generate that level of cash in one quarter will be difficult."

Segments & Mix Shift

Krishna Bodanapu: "the overarching principle would follow is wherever there is manufacturing, the whole deal is owned by Cyient DLM. And if Cyient needs to support on the engineering and the design elements, Cyient will support."

Capacity, Facilities & Leadership

Anthony Montalbano: "This is a key addition to our leadership team and he is really a differentiator in the markets as far as having the ability to truly bring design-led solutions from a manufacturing perspective."

Guidance & Commitments

CommitmentSpecificsTimeline
Order book maintenanceMaintain order book around INR2,000 crores, subject to pipeline conversionNext few quarters
Q4 EBITDA marginReach around 10% to 10.5% (expectation, not guidance)Q4 FY24
Medium-term EBITDA marginInch toward 11%-12% as mix changes and scale benefits accrueNo fixed date
Inventory daysReduce to ~120 daysQ4 FY24
Free cash flowPositive free cash flow expectedQ4 FY24
Interest costSubstantial reduction as remaining working capital loans are paid offQ4 FY24
SG&A investmentNo significant further SG&A investment expected; expenses have peakedFrom Q4 FY24 onward
New Mysore facilityLeased software park, minimal capex (~$2 mn), support medical and industrial growthNext financial year
M&ASeveral conversations in advanced stages; management hopes to close an LOIThis quarter (aspiration)
Order book breakup disclosureMay start providing order book breakup by industryFrom next call

Key Metrics

MetricQ3 FY24
RevenueINR321 cr, +49.7% YoY, highest ever quarterly revenue
Revenue (9M FY24)INR830 cr, +49.6% YoY, close to full-year FY23 revenue
EBITDAINR29.4 cr, +42.7% YoY
EBITDA margin9.2%, down 45 bps YoY
EBITDA margin (9M FY24)8.8%, down 132 bps YoY due to planned SG&A investments
Profit after taxINR18.4 cr, +222.6% YoY, driven by other income and volume growth
Profit after tax (9M FY24)+100% YoY
Order backlogINR2,294 cr, stable, ROI marginally higher than Q3
Order intake$41.8 mn
New awards$10 mn, spread over three to four years, primarily defence
Inventory days137 days, marginally reduced QoQ; target 120 days short term, 90 days medium term
Free cash flow-INR34 cr consumed in Q3; positive free cash flow expected in Q4
IPO proceeds utilizationINR80 cr consumed towards working capital; external loans repaid
Capacity utilization~50% overall; Mysore near peak, Hyderabad still low
Defence revenue mix30–35% of overall revenue, expected to continue through the year